Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LGH447 in Japanese Patients With Relapsed/Refractory Multiple Myeloma
NCT02160951Phase 1Completed
- Sponsor
- Novartis
- Start
- Sep 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PIM447 in multiple myeloma (MM), sponsored by Novartis. Primary endpoint: Incidence rate of dose limiting toxicities at 28 days. Started Sep 2014; status: completed.
02
Drugs
PIM447
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02160951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02160951.